Grace Therapeutics GRCE
NASDAQ GRCE
$1.75 -0.06 (-3.31%)
At close: Nov 16, 2026 · 4:00 PM EST

Grace Therapeutics (GRCE) Convertible Debt (2017 - 2020)

Updated

Grace Therapeutics' Convertible Debt came in at $187,000 for fiscal Q4 2020 (quarter ended Mar 31, 2020), down 88.2% from $1.58 million a year earlier.

Analysis

Grace Therapeutics (GRCE) Convertible Debt (2017 - 2020) Analysis & Trends

  • Going back by fiscal year, Convertible Debt was $1.58 million in FY2019.
  • The fiscal Q4 2020 figure represents the lowest quarterly Convertible Debt since fiscal Q1 2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,276.89 Bn 1,250.50 Bn 20.46 Bn
2 Johnson & Johnson 681.31 Bn 601.18 Bn 17.30 Bn
3 AbbVie 520.63 Bn 488.64 Bn 13.12 Bn
4 Merck 357.22 Bn 320.16 Bn 13.19 Bn
5 Novartis Ag 310.90 Bn 284.14 Bn -
6 Astrazeneca 285.12 Bn 258.77 Bn 13.26 Bn
7 Amgen 250.23 Bn 201.89 Bn 7.58 Bn
8 Gilead Sciences 207.56 Bn 182.67 Bn 6.73 Bn
9 Pfizer 164.42 Bn 111.77 Bn 12.56 Bn
10 Grace Therapeutics 35.10 Mn -35.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 187,000.00
Mar 31, 2019 1.58 Mn
Jun 30, 2017 -30,017.09
API Access

Grace Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=GRCE&period=max&api_key=YOUR_API_KEY